BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260928T120000
DTEND;TZID=America/New_York:20260928T133000
DTSTAMP:20260928T050339
CREATED:20260722T131417Z
LAST-MODIFIED:20260917T144131Z
UID:10001757-1790596800-1790602200@lifescievents.com
SUMMARY:CAMP4 Therapeutics Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder
DESCRIPTION:Join CAMP4 Therapeutics for a virtual Analyst Day featuring presentations and Q&A led by CAMP4’s executive leadership team\, with participation from patient advocates and a leading KOL. \nDiscussions will focus on CMP-002\, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder\, including clinical trial design for the company’s FIH Phase 1/2 clinical trial expected to initiate in Q4 2026. \nStéphane Auvin\, MD\, PhD (Robert Debré University Hospital\, Université Paris Cité) will join to discuss the unmet need and current treatment landscape for SYNGAP1-related disorder. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/ko3t1sl/.
URL:https://lifescievents.com/event/ko3t1sl/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/banner-healthy-second-line.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260928T123000
DTEND;TZID=America/New_York:20260928T140000
DTSTAMP:20260928T050339
CREATED:20260728T160510Z
LAST-MODIFIED:20260917T144206Z
UID:10001762-1790598600-1790604000@lifescievents.com
SUMMARY:Quince Therapeutics Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Potential Role for LAM-001 as a New Therapeutic Option
DESCRIPTION:Join Quince Therapeutics for a virtual key opinion leader (KOL) event featuring PH-ILD experts Aaron B. Waxman\, MD\, PhD (Brigham and Women’s Hospital) and Paul Yu\, MD\, PhD (Massachusetts General Hospital)\, as well as BOS expert Steven Hays\, MD (UCSF Health)\, who will join company management to discuss the unmet need and current treatment landscape for PH-ILD and BOS. \nThe event will provide an overview of LAM-001\, the Company’s proprietary investigational once-daily inhaled DPI formulation of rapamycin (mTOR inhibitor)\, currently in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS). The KOLs will discuss mTOR inhibition as a potentially disease modifying mechanism of action across these conditions\, focusing on its potential role in suppressing pulmonary smooth muscle hyperproliferation\, limiting fibroblast driven vascular and interstitial remodeling\, and modulating inflammatory signaling\, along with the unique potential advantages of delivering therapy through an inhaled route. The KOLs will review current treatment options as well as the emerging treatment landscape for each condition. Data from the recently presented Phase 2a trial of LAM-001 in pulmonary hypertension will be reviewed as well as the design and objectives of the ongoing Phase 2 BOS and Phase 2b PH-ILD studies. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/gr59hlp/.
URL:https://lifescievents.com/event/gr59hlp/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Events-Banners_2-7-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260929T090000
DTEND;TZID=America/New_York:20260929T100000
DTSTAMP:20260928T050339
CREATED:20260904T191310Z
LAST-MODIFIED:20260917T144238Z
UID:10001789-1790672400-1790676000@lifescievents.com
SUMMARY:Legend Biotech Virtual KOL Event: CARVYKTI® (cilta-cel) Five-Year CARTITUDE-2 Data in Earlier-Line Multiple Myeloma
DESCRIPTION:Join Legend Biotech for a virtual KOL event featuring Leyla Shune\, MD (Franciscan Health) and Marco Davila\, MD\, PhD (Roswell Park Comprehensive Cancer Center)\, who will join company management to discuss CARVYKTI for the treatment of relapsed or refractory multiple myeloma (RRMM). \nThe event will provide an overview of the latest CARVYKTI data from Legend’s poster presentations at the International Myeloma Society (IMS) Annual Meeting. CARVYKTI is the first CAR-T therapy for multiple myeloma approved after one other treatment has not worked or has stopped working\, given as a one-time infusion. Management will review the five-year follow-up CARTITUDE-2 Cohort A data\, a Phase 2 study cohort evaluating ciltacabtagene autoleucel (cilta-cel) in patients with RRMM who had received 1-3 prior lines of therapy\, real world outcome data from the eMMpower-CART study\, and first results from a noninterventional\, prospective post-authorization safety study in RRMM. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/lzt23wo/.
URL:https://lifescievents.com/event/lzt23wo/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/09/Legend-Banner-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260930T110000
DTEND;TZID=America/New_York:20260930T123000
DTSTAMP:20260928T050339
CREATED:20260723T144510Z
LAST-MODIFIED:20260917T195113Z
UID:10001759-1790766000-1790771400@lifescievents.com
SUMMARY:ProQR Therapeutics Virtual Investor and Analyst Educational Event: NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing
DESCRIPTION:Join ProQR Therapeutics for a virtual investor and analyst educational event featuring Gideon Hirschfield\, MA (Oxon)\, MB BChir (Cantab)\, FRCP\, PhD (Toronto Centre for Liver Disease)\, who will join company management to discuss the unmet need and current treatment landscape in cholestatic liver disease\, with a focus on biliary atresia. \nThe event will provide an in-depth review of the role of bile acids and NTCP modulation in cholestatic liver disease\, with a focus on biliary atresia. ProQR will review the recently reported AX-0810 Phase 1 target engagement data and discuss the translational rationale and clinical development strategy for NTCP modulation in biliary atresia\, including the framework for evaluating upcoming next-generation AX-0811 Phase 1 data and its potential to treat cholestatic disease. \nA live question and answer session with covering analysts will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/prk62s0/.
URL:https://lifescievents.com/event/prk62s0/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/ProQR-Banner-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260930T130000
DTEND;TZID=America/New_York:20260930T143000
DTSTAMP:20260928T050339
CREATED:20260824T182152Z
LAST-MODIFIED:20260927T230031Z
UID:10001780-1790773200-1790778600@lifescievents.com
SUMMARY:Sagimet Biosciences Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US
DESCRIPTION:Join Sagimet Biosciences for a virtual event featuring key opinion leader (KOL) Julie Harper\, MD\, Founding Director and past President of the American Acne and Rosacea Society. Dr. Harper will join Company management for a review of the 52-week data from license partner Ascletis’ open-label Phase 3 clinical trial of denifanstat in moderate to severe acne vulgaris in China (OLE)\, and an update on the Company’s planned AURORA Phase 3 clinical trial of denifanstat for the treatment of moderate to severe acne in the U.S. \nIn the OLE\, subjects treated with denifanstat showed improvements in all efficacy endpoints (secondary endpoints of the trial) beyond those observed at 12 weeks. Denifanstat was generally well tolerated throughout the trial. These results will be presented at the European Academy of Dermatology and Venereology Congress (EADV 2026)\, building on the topline results announced in February 2026. \nSagimet’s AURORA Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S. is expected to initiate in the fourth quarter of 2026. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor with potential as a novel mechanism of action to address moderate to severe acne\, a condition that impacts more than 10 million people annually in the U.S. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sdj928tn/.
URL:https://lifescievents.com/event/sdj928tn/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Sagimet-Banner-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261005T080000
DTEND;TZID=America/New_York:20261005T093000
DTSTAMP:20260928T050339
CREATED:20260803T151752Z
LAST-MODIFIED:20260917T144453Z
UID:10001767-1791187200-1791192600@lifescievents.com
SUMMARY:Compugen Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update
DESCRIPTION:Join Compugen for a virtual key opinion leader (KOL) event featuring Oladapo Yeku\, MD\, PhD\, FACP (Harvard Medical School\, Massachusetts General Hospital)\, who will join company management to discuss the evolving treatment landscape in ovarian cancer. \nDr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial of COM701\, a potential first-in-class anti-PVRIG antibody\, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC)\, with median progression-free survival data from the interim analysis expected by Q1 2027. \nCompugen’s Research and Discovery team will also provide an update on expanded capabilities of Unigen™\, its AI-based target discovery platform\, which enables the discovery of novel cancer immunotherapy drug targets and the continuous development of first-in-class drugs. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/tp28kry/.
URL:https://lifescievents.com/event/tp28kry/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Events-Banners_2-9.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261006T100000
DTEND;TZID=America/New_York:20261006T113000
DTSTAMP:20260928T050339
CREATED:20260727T200458Z
LAST-MODIFIED:20260917T144523Z
UID:10001761-1791280800-1791286200@lifescievents.com
SUMMARY:Faeth Therapeutics Virtual KOL Event: Multi-Nodal Inhibition for the Treatment of Endometrial Cancer
DESCRIPTION:Join Faeth Therapeutics for a virtual key opinion leader (KOL) event featuring Marcus Goncalves\, MD\, PhD (NYU Langone Health & Scientific Co-founder\, Faeth Therapeutics)\, who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human cancer and the company’s upcoming Phase 2 readout in endometrial cancer. \nThe event will provide an overview of the PAM pathway\, a critical signaling network that regulates cell growth\, survival\, and metabolism\, and one of the most frequently altered oncogenic signaling pathways in human cancer. Management will compare single-node inhibition with Faeth’s vertical multi-node approach\, called PIKTOR\, a therapeutic combination of the PI3K inhibitor serabelisib and mTOR inhibitor sapanisertib. During the call\, management will highlight recently-presented translational work which led to the dose and schedule of PIKTOR currently being evaluated in its Phase 2 trial as well as clinical data from a prior Phase 1b trial. Management will also highlight the unmet need for novel therapies in endometrial cancer\, where approximately 80% of tumors harbor a PAM pathway alteration\, and treatment options following checkpoint inhibitor therapy remain limited. Topline data from the company’s Phase 2 trial is anticipated by year-end. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/ha5t63x/.
URL:https://lifescievents.com/event/ha5t63x/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Events-Banners_2-6.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261015T100000
DTEND;TZID=America/New_York:20261015T113000
DTSTAMP:20260928T050339
CREATED:20260831T183130Z
LAST-MODIFIED:20260923T160607Z
UID:10001784-1792058400-1792063800@lifescievents.com
SUMMARY:enGene Therapeutics Inc. Detalimogene plus Surfactant KOL Webinar
DESCRIPTION:Join enGene for a webinar that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development. Two community key opinion leaders (KOLs) from Colorado Urology\, David J. Cahn\, MD and Suzanne B. Merrill\, MD\, FACS\, will review clinical case studies and discuss various real-world treatment considerations. \nSurfactants have been shown to boost efficacy with other NMIBC gene therapies in preclinical models and were subsequently incorporated into clinical development of those gene therapies. enGene is currently enrolling high-risk\, BCG-unresponsive NMIBC patients with CIS in an additional cohort in its ongoing LEGEND trial\, which incorporates a short surfactant bladder rinse (generic name: polidocanol) prior to intravesical administration of detalimogene. Detalimogene is an investigational\, non-viral gene therapy designed for direct bladder instillation to treat high-risk\, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/egjs02p/.
URL:https://lifescievents.com/event/egjs02p/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/enGene-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261020T143000
DTEND;TZID=America/New_York:20261020T160000
DTSTAMP:20260928T050339
CREATED:20260728T194941Z
LAST-MODIFIED:20260917T144636Z
UID:10001764-1792506600-1792512000@lifescievents.com
SUMMARY:vTv Therapeutics Virtual KOL Event to Discuss Type 1 Diabetes\, the Significant Unmet Medical Need of Hypoglycemia\, and the Cadisegliatin Phase 3 Program
DESCRIPTION:Join vTv Therapeutics for a virtual KOL event featuring leading T1D experts Schafer Boeder\, MD (Paradigm Clinical Research\, University of California San Diego) and Klara Klein\, MD\, PhD (University of North Carolina at Chapel Hill School of Medicine) who will join company management to discuss: \n\nChallenges in the type 1 diabetes (T1D) treatment landscape\nRisks of hypoglycemia and the experience of living with T1D\nCadisegliatin\, vTv’s novel\, potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of T1D\nAn overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D\n\nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/vw02ypl/.
URL:https://lifescievents.com/event/vw02ypl/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/Events-Banners_2-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261027T140000
DTEND;TZID=America/New_York:20261027T170000
DTSTAMP:20260928T050339
CREATED:20260629T174707Z
LAST-MODIFIED:20260916T210600Z
UID:10001748-1793109600-1793120400@lifescievents.com
SUMMARY:LB Pharma R&D Day: Advancing LB‑102 with a Focus on Schizophrenia Treatment
DESCRIPTION:Join LB Pharmaceuticals for an in-person and virtual R&D Day featuring Roger S. McIntyre\, MD\, FRCPC (University of Toronto)\, alongside Heather Turner (CEO)\, Susan G. Kozauer (CMO)\, Kaya Pai Panandiker (CCO)\, Gad Soffer (COBO)\, and Joe Miller (CFO)\, as the Company looks ahead to its upcoming topline data readout in schizophrenia. \nLB-102 is a novel\, once-daily oral selective antagonist of D2\, D3 and 5HT7 receptors with a unique bimodal mechanism. It is being developed by LB Pharma for the treatment of schizophrenia\, bipolar depression\, the adjunctive treatment of major depressive disorder\, as well as other neuropsychiatric disorders\, and has the potential to be the first therapy with this unique mechanism approved for neuropsychiatric disorders in the United States. \nTopics will include: \n\nNew scientific insights on LB-102’s unique mechanism of action that underlies the emerging clinical profile and opportunity across a wide variety of brain disorders\nDiscussion of the Phase 3 trial program in schizophrenia\, its upcoming topline data readout in the first half of 2027\, and ongoing pre-commercial planning activities\n\nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/gj28t6w/.
URL:https://lifescievents.com/event/gj28t6w/
LOCATION:Midtown\, New York and Live Webcast\, Midtown\, New York and Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/06/LB-Pharma-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261112T080000
DTEND;TZID=America/New_York:20261112T100000
DTSTAMP:20260928T050339
CREATED:20260918T182001Z
LAST-MODIFIED:20260923T161828Z
UID:10001792-1794470400-1794477600@lifescievents.com
SUMMARY:Praxis Precision Medicines Investor Day
DESCRIPTION:Please join Praxis Precision Medicines for an Investor Day in New York. \nMore detailed information on the agenda and speakers will be provided closer to the event. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/pvs39fn/.
URL:https://lifescievents.com/event/pvs39fn/
LOCATION:Midtown\, New York and Live Webcast\, Midtown\, New York and Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/09/Events-Banners_2-14.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20261116T170000
DTEND;TZID=Europe/London:20261116T190000
DTSTAMP:20260928T050339
CREATED:20260805T182940Z
LAST-MODIFIED:20260923T161716Z
UID:10001772-1794848400-1794855600@lifescievents.com
SUMMARY:IDEAYA Biosciences R&D Day Event
DESCRIPTION:Please join IDEAYA Biosciences for an R&D Day in London where management and key opinion leader Frank McCormick\, Ph.D.\, of the UCSF Helen Diller Family Comprehensive Cancer Center\, will outline the company’s current clinical development strategy in MTAP/CDKN2A and KRAS solid tumors\, with a particular focus on pancreatic cancer (PDAC). \nThe event will include new preclinical data and perspectives on rational combination strategies IDEAYA is conducting to target the tumor heterogeneity and adaptive plasticity in PDAC and other priority solid tumor indications. \nMore detailed information on the agenda and speakers will be provided closer to the event. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/izl51pw/.
URL:https://lifescievents.com/event/izl51pw/
LOCATION:The Savoy Hotel\, Strand\, London WC2R 0EZ\, United Kingdom\, The Savoy Hotel\, Strand\, London WC2R 0EZ\, United Kingdom
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/IDEAYA-Banner-scaled.png
END:VEVENT
END:VCALENDAR